Translate page

English English
en Englishbg Bulgarianzh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchfi Finnishfr Frenchde Germanel Greekiw Hebrewhi Hindiid Indonesianit Italianja Japaneseko Koreanmk Macedonianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishth Thaitr Turkishvi Vietnamese

Virtual Education

COLT Meeting 2019: CML therapy - state of science

-- Virtual Education Program: 2019 Edition

 

Presentations from the COLT Meeting 2019

We are pleased to make available a series of presentations from the COLT Meeting 2019, a CML Opinion Leader Training that took place in Adelaide (Australia). Topics cover; CML therapy - state of science, management of CML, practicalities and monitoring TFR and Ph+ALL.

Timothy Hughes

 David Yeung 3 Devendra Hiwase

Session 1: CML therapy - state of science
Chair: Prof. Tim Hughes

  • Frontline Therapy for CML 
    (Prof Tim Hughes)
  • When frontline therapy fails
    (Dr David Yeung)
  • CML - Beyond chronic phase
    (Dr Devendra Hiwase)

 

 


Timothy Hughes

  

 

Frontline Therapy for CML
Prof. Tim Hughes, SAHMRI / University of Adelaide

  • Consensus and controversies  in frontline therapy for CML
  • Relative risk of CML patients according to clinical and haematological data at diagnosis
  • Heterogeneity of response to TKI therapy in CML
  • Risk-adapted/goal specific treatment schema
  • Frontline therapy selection
  • Results from the TIDEL II trial in Australia/NZ
  • Future of CML management: Bioassay and molecular dynamics driven
  • Conclusions
 

 
David Yeung 3  


When frontline therapy fails
Dr David Yeung - SAHMRI / Royal Adelaide Hospital

  • LASOR/DASCERN - failure to achieve 2019 ELN goals
  • TIDEL II - failure to achieve optimal ELN 2013 treatment goals
  • ENESTCmr - failure to achieve deep molecular response
  • Ponatinib - drug of last resort
  • Asciminib (ABL001) - rising star?

Devendra Hiwase		  

 

CML - Beyond chronic phase
Dr Devendra Hiwase - SA Pathology / Royal Adelaide Hospital

  • Diagnostic and management issues in CML-AP
    • Definitions of accelerated phase
    • Staging of chronic myeloid leukemia in the imatinib era
    • Survival benefit with Imatinib in CML-AP
    • Study results on NIL and DAS in patients with CML-AP
    • Imatinib vs. allogeneic SCT in CML-AP patients
    • Treatment strategy recommendations for CML-AP
    • Patient case
  • Diagnostic criteria and management of blast crisis
    • Transformation to blast crisis
    • Survival of CML-BC patients: German CML studies I to IIIA
    • Outcome of blast crisis in the era of TKI therapy
    • Cytogenetic landscape and impact in blast phase of CML in the era of TKI therapy
    • Management issues in CML-BC
    • IM and 2nd generation TKI's in BC patients
    • Patient case